190 related articles for article (PubMed ID: 9593049)
21. G3139, a BCL-2 antisense oligo-nucleotide, in AML.
Marcucci G; Stock W; Dai G; Klisovic MI; Maharry K; Shen T; Liu S; Sher DA; Lucas D; Zwiebel A; Larson RA; Caligiuri MA; Bloomfield CD; Chan KK; Grever MR; Byrd JC
Ann Hematol; 2004; 83 Suppl 1():S93-4. PubMed ID: 15124691
[No Abstract] [Full Text] [Related]
22. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
23. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
24. Progress in antisense therapeutics.
Crooke ST
Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
[TBL] [Abstract][Full Text] [Related]
25. [Current status of antisense drugs].
Li XJ
Sheng Li Ke Xue Jin Zhan; 2000 Apr; 31(2):115-9. PubMed ID: 12545727
[TBL] [Abstract][Full Text] [Related]
26. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.
Iversen PL
Curr Opin Mol Ther; 2001 Jun; 3(3):235-8. PubMed ID: 11497346
[TBL] [Abstract][Full Text] [Related]
27. Progress in antisense therapeutics discovery and development.
Crooke ST
Ciba Found Symp; 1997; 209():158-64; discussion 164-8. PubMed ID: 9383575
[TBL] [Abstract][Full Text] [Related]
28. Antisense transforming growth factor-beta 1 in wound healing.
Chung HT; Choi BM; Jun CD; Park SD; Rim JS
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):257-61. PubMed ID: 9212921
[No Abstract] [Full Text] [Related]
29. Still looking for the real GEM.
GMHC Treat Issues; 1996 Apr; 10(4):9. PubMed ID: 11363711
[TBL] [Abstract][Full Text] [Related]
30. Antisense therapeutics.
Crooke ST
Biotechnol Genet Eng Rev; 1998; 15():121-57. PubMed ID: 9573607
[No Abstract] [Full Text] [Related]
31. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
[TBL] [Abstract][Full Text] [Related]
32. Protein kinase C as a target for cancer therapy.
Glazer RI
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
[No Abstract] [Full Text] [Related]
33. Preclinical and clinical experience of antisense therapy for solid tumors.
Webb MS; Zon G
Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
[TBL] [Abstract][Full Text] [Related]
34. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents.
Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Pomatico G; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):141-5. PubMed ID: 9593054
[No Abstract] [Full Text] [Related]
35. [Prospects of a more selective chemotherapy with antisense oligonucleotides].
Le Doan T; Etoré F; David DF; Tenu JP
Ann Med Interne (Paris); 1996; 147(8):542-52. PubMed ID: 9137681
[No Abstract] [Full Text] [Related]
36. Antisense has growing pains.
Gura T
Science; 1995 Oct; 270(5236):575-7. PubMed ID: 7570012
[No Abstract] [Full Text] [Related]
37. Antisense strategies: functions and applications in immunology.
Varga LV; Tóth S; Novák I; Falus A
Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355
[TBL] [Abstract][Full Text] [Related]
38. Delivery is key: lessons learnt from developing splice-switching antisense therapies.
Godfrey C; Desviat LR; Smedsrød B; Piétri-Rouxel F; Denti MA; Disterer P; Lorain S; Nogales-Gadea G; Sardone V; Anwar R; El Andaloussi S; Lehto T; Khoo B; Brolin C; van Roon-Mom WM; Goyenvalle A; Aartsma-Rus A; Arechavala-Gomeza V
EMBO Mol Med; 2017 May; 9(5):545-557. PubMed ID: 28289078
[TBL] [Abstract][Full Text] [Related]
39. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
40. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
de Fabritiis P; Calabretta B
Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
